Ameriprise Financial Inc Fibrogen Inc Transaction History

Ameriprise Financial Inc

$381 Billion
Q3 2024

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.89 - $2.36 $149,695 - $396,944	-168,197 Reduced 81.88%	37,227 $33,000
Q1 2024 May 15, 2024	SELL	$0.73 - $2.73 $57,580 - $215,336	-78,878 Reduced 27.74%	205,424 $482,000
Q4 2023 Feb 14, 2024	SELL	$0.38 - $0.91 $9 - $22	-25 Reduced 0.01%	284,302 $253,000
Q3 2023 Nov 14, 2023	BUY	$0.79 - $2.83 $205,802 - $737,243	260,510 Added 1093.8%	284,327 $244,000
Q2 2023 Aug 14, 2023	SELL	$2.49 - $20.59 $2,201 - $18,201	-884 Reduced 3.58%	23,817 $64,000
Q1 2023 May 15, 2023	SELL	$15.95 - $25.18 $48,567 - $76,673	-3,045 Reduced 10.97%	24,701 $460,000
Q4 2022 Feb 14, 2023	BUY	$13.27 - $17.73 $1,061 - $1,418	80 Added 0.29%	27,746 $444,000
Q3 2022 Nov 14, 2022	BUY	$11.4 - $14.6 $315,392 - $403,923	27,666 New	27,666 $360,000
Q4 2021 Feb 14, 2022	SELL	$9.93 - $15.39 $292,220 - $452,896	-29,428 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$10.18 - $26.64 $195,578 - $511,807	-19,212 Reduced 39.5%	29,428 $301,000
Q2 2021 Aug 16, 2021	SELL	$18.57 - $35.68 $366,330 - $703,859	-19,727 Reduced 28.85%	48,640 $1.3 Million
Q1 2021 May 17, 2021	SELL	$31.0 - $55.72 $162,781 - $292,585	-5,251 Reduced 7.13%	68,367 $2.37 Million
Q4 2020 Feb 12, 2021	SELL	$37.09 - $48.97 $50,924 - $67,235	-1,373 Reduced 1.83%	73,618 $2.73 Million
Q3 2020 Nov 16, 2020	SELL	$40.47 - $45.5 $673,704 - $757,438	-16,647 Reduced 18.17%	74,991 $3.08 Million
Q2 2020 Aug 14, 2020	SELL	$32.57 - $42.83 $755,917 - $994,041	-23,209 Reduced 20.21%	91,638 $3.71 Million
Q1 2020 May 15, 2020	BUY	$23.3 - $45.96 $213,078 - $420,304	9,145 Added 8.65%	114,847 $3.99 Million
Q4 2019 Feb 14, 2020	BUY	$34.58 - $48.06 $110,794 - $153,984	3,204 Added 3.13%	105,702 $4.53 Million
Q3 2019 Nov 14, 2019	SELL	$36.98 - $48.45 $296,616 - $388,617	-8,021 Reduced 7.26%	102,498 $3.79 Million
Q2 2019 Aug 14, 2019	SELL	$35.13 - $55.53 $1.62 Million - $2.56 Million	-46,132 Reduced 29.45%	110,519 $4.99 Million
Q1 2019 May 15, 2019	BUY	$42.83 - $59.91 $5.16 Million - $7.22 Million	120,503 Added 333.36%	156,651 $8.51 Million
Q4 2018 Feb 14, 2019	SELL	$37.97 - $60.16 $793,610 - $1.26 Million	-20,901 Reduced 36.64%	36,148 $1.67 Million
Q3 2018 Nov 14, 2018	BUY	$56.3 - $67.25 $284,483 - $339,814	5,053 Added 9.72%	57,049 $3.47 Million
Q2 2018 Aug 14, 2018	BUY	$44.9 - $64.95 $1.16 Million - $1.68 Million	25,804 Added 98.52%	51,996 $3.26 Million
Q1 2018 May 15, 2018	SELL	$45.35 - $61.65 $12,924 - $17,570	-285 Reduced 1.08%	26,192 $1.21 Million
Q4 2017 Feb 12, 2018	SELL	$41.95 - $60.1 $290,042 - $415,531	-6,914 Reduced 20.71%	26,477 $1.26 Million
Q3 2017 Nov 07, 2017	BUY	$33.4 - $53.9 $1.12 Million - $1.8 Million	33,391	33,391 $1.8 Million

Others Institutions Holding FGEN

# of Institutions

Shares Held

47.1M

Call Options Held

387K

Put Options Held

672K

View Full List

About FIBROGEN INC

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $31.9M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

More about FGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.

Account